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This year, the Lasker Foundation recognizes Albert Starr and Alain Carpentier for their 
development of effective treatments for valvular heart disease. Their innovative work is a 
model of interdisciplinary basic and clinical research and has benefited millions of people.On September 28, 2007, the Albert 
Lasker Award for Clinical Medical 
Research will be conferred on Albert 
Starr of the Providence Heart and 
Vascular Institute, Providence Health 
System, and the Oregon Health and 
Science University in Portland, Ore-
gon and Alain Carpentier of the Hôpi-
tal European Georges Pompidou in 
Paris, France. They are recognized 
for developing effective treatments 
for valvular heart disease, interven-
tions that save lives and dramatically 
improve the quality of life of nearly 
half a million patients annually.
The heart is a remarkable pump, 
rhythmically beating ~3 billion times 
without fail in the course of a normal 
lifetime, propelling oxygen, nutrients, 
and blood cells throughout the body 
and varying its output according to 
metabolic need. This astoundingly 
efficient mechanism relies upon four 
chambers that contract synchro-
nously and the actions of four valves 
that provide directional blood flow 
(Figure 1). The right atrium receives 
venous blood from the systemic cir-
culation, and its contraction passes 
blood through the tricuspid valve, fill-
ing the right ventricle; contraction of 
the right ventricle then sends blood 
through the pulmonic valve into the 
pulmonary artery and then the lung 
capillaries, where it is oxygenated. 
This oxygenated blood is returned to 
the left atrium, which passes blood 
through the mitral valve to the left 
ventricle that then contracts, pump-
ing blood through the aortic valve into 
the arterial circulation via the aorta. 
From here, the blood passes into suc-
cessively smaller vessels, ultimately 
delivering oxygen and nutrients to 
tissues; this blood then flows into the 
venous circulation, ultimately return-
ing to the right atrium. The heart must 
pump continuously throughout life, 
and failure of this mechanism for even 
a few seconds results in loss of con-
sciousness; failure for a few minutes 
results in death.
The four heart valves all open 
in response to pressure from the 
proximal side and close in response 
to pressure from the distal side, 
thereby producing directional flow. 
Should one of these valves fail to 
open properly, the flow of blood 
will be impaired and will only occur 
under higher pressure from the 
proximal side. Alternatively, should 
a valve become leaky, blood can 
flow in both antegrade and retro-
grade directions, with resumption of 
the necessary antegrade flow only 
when larger total volumes of blood 
are pumped.
Diseases of the heart valves were 
well-described as far back as the 
17th and 18th centuries. It is now rec-
ognized that a variety of antecedent 
conditions result in valvular heart dis-
ease. These include rheumatic fever 
due to an aberrant immune response 
to group A streptococcal infection; 
abnormal development of valve 
structures resulting in congenital 
malformations; calcification of valves 
with aging; mitral valve prolapse; and 
ischemic heart disease. It is estimated 
that 15 million people worldwide have 
valvular heart disease due to rheu-
matic fever alone (WHO, 2004). The 
clinical consequences and natural 
histories of the stenotic and regurgi-
Figure 1. Anatomy of the Heart
This coronal section of the human heart shows the anatomic relationships of the four heart cham-
bers, its valves, and the great vessels that receive the output of the right and left ventricles. Image 
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tant lesions of each valve (narrowing 
of the valve orifice and failure of valve 
closure, respectively) have been well 
described. If left untreated, valvular 
defects typically lead first to impaired 
capacity for exercise, then to overt 
congestive heart failure, then to 
death (Bonow and Braunwald, 2005). 
Indeed, this was the typical outcome 
of these disorders until the work of 
this year’s Lasker award recipients.
Prior to the development of cardio-
pulmonary bypass in 1953, which for 
the first time permitted open heart 
surgery, the treatment of valvular 
heart disease was limited to desper-
ate efforts to blindly open stenotic 
valves with a finger or a hooked knife 
in the beating heart; there were no 
effective therapies for regurgitant 
valves. With the advent of cardio-
pulmonary bypass, it was recog-
nized that diseased valves might 
be surgically replaced; this initiated 
an aggressive search for a suitable 
mechanical valve.
Early efforts identified a number of 
daunting obstacles to success. First 
and foremost, the introduction of 
nonbiological materials into the car-
diovascular system had a high pro-
pensity to induce thrombosis, result-
ing in obstruction of the valve orifice 
or the showering of emboli to distant 
organs, both with catastrophic con-
sequences. In addition, the valve had 
to be remarkably durable, function-
ing without fail for the duration of the 
patient’s life.
Into this setting, an innovative 
and accomplished mechanical engi-
neer, Lowell Edwards, approached a 
young cardiothoracic surgeon at the 
University of Oregon, Albert Starr, 
with a proposal to develop an arti-
ficial heart. Starr, recognizing the 
enormous complexity of such an 
endeavor, persuaded Edwards to 
instead focus on valve replacement 
as a more tractable problem. Rap-
idly, they converged on a design for 
their artificial valve that was quite 
unlike the leafleted native valve. They 
designed a ball-in-cage valve in 
which the seated ball would be dis-
placed to the end of its cage by pres-
sure from the proximal side, allow-
ing blood to flow, and then would 972 Cell 130, September 21, 2007 ©2007become reseated in the closed posi-
tion due to increasing pressure on 
the distal side, preventing retrograde 
flow. This very simple design (like 
one developed as a bottle stopper in 
the 19th century) had been adopted 
as a valve inserted into the descend-
ing aorta (Hufnagel, 1951) but largely 
had been abandoned. Nonetheless, 
the design was attractive for its sim-
plicity and the hope that the constant 
movement of the unattached poppet 
(ball) might inhibit thrombus forma-
tion (Figure 2).
Starr and Edwards went through 
a number of design modifications 
and experimentation with different 
materials for the poppet, struts, and 
annulus. Promising surgical experi-
mentation in dogs, along with devel-
opment of regimens for pharmaco-
logical inhibition of thrombosis, led 
to the first artificial valve implants into 
humans within two years of the initial 
meeting between Edwards and Starr. 
The first patients undergoing valve 
replacement with the Starr-Edwards 
valve were carefully selected for hav-
ing intractable congestive heart fail-
ure. A report of the experience of the 
first eight patients undergoing mitral 
valve replacement was published in 
1961 and caused a sensation. Not 
only were there six long-term survi-
vors, but recipients showed dramatic 
improvements in hemodynamics 
and equally dramatic symptomatic 
improvements, even returning to 
their normal daily activities (Starr and 
Edwards, 1961).
Figure 2. The Starr-Edwards Prosthetic 
Heart Valve
Two views of the valve are shown: one with 
the poppet (ball) seated in the closed position 
(left), and the other with the poppet displaced 
in the open position (right). Image courtesy of 
Edwards Lifesciences. Elsevier Inc.The Starr-Edwards valve quickly 
went into commercial production 
through a company founded by 
Edwards, and its wide implementa-
tion revolutionized the treatment of 
valvular heart disease. The Starr-
Edwards valve is still in use, virtually 
unchanged since 1965, and has been 
implanted in over 250,000 patients 
(Gott et al., 2003). Edwards, who died 
in 1982, deservedly shares credit with 
Starr for his key role in the develop-
ment and dissemination of prosthetic 
valve replacement.
The success of the Starr-Edwards 
valve spurred further development 
efforts, and there are currently five 
additional mechanical prosthetic 
valves approved for human use by 
the US Food and Drug Administra-
tion. Among these, the St. Jude bile-
aflet valve, first implanted in 1977, 
has become the most widely used 
prosthetic valve, with over 1.3 million 
valves implanted. Although this valve 
more closely mimics native valve 
function, randomized controlled trials 
have documented no significant dif-
ferences in symptoms or outcomes 
between the Starr-Edwards valve 
and the St. Jude valve (Murday et al., 
2003).
In addition to outstanding surgical 
skill, Starr also proved to be a superb 
clinical investigator. He pioneered 
the maintenance of a detailed regis-
try of all his patients receiving valve 
replacement with careful monitoring 
of complications; the registry now 
lists 20,000 patients with up to 40 
years of followup (Gao et al., 2004). 
The results have yielded a trove of 
clinical information documenting the 
early and late complications of valve 
replacement, permitting ongoing 
improvements in valve design and 
the treatment of recipients (Herr et 
al., 1965). Surgical mortality has been 
reduced to a few percent and more 
than 25% of prosthetic valve recipi-
ents survive for 25 years. The Starr-
Edwards valve and other prosthetic 
heart valves have proved extraordi-
narily durable, with structural failure 
virtually nonexistent. Nonetheless, 
about half the deaths among valve 
recipients are due to complications of 
the artificial valve; chief among these 
are hemorrhage arising from life-long 
treatment with anticoagulants, throm-
boembolism despite anticoagulant 
treatment, infection of the valve, and 
the development of leaks at the surgi-
cal margins.
The risk of hemorrhage and throm-
boembolism in patients with mechan-
ical valve replacement led to the real-
ization that development of biological 
or bioprosthetic valves free of these 
complications would be advanta-
geous. Alain Carpentier, a cardiotho-
racic surgeon, and his colleagues in 
Paris recognized that xenografts of 
heart valves from other species rep-
resented a possible path forward. 
These heart valves had the obvious 
advantage of being well-adapted to 
their purpose, could be harvested 
under rigorously controlled condi-
tions, and because of their natural 
nonthrombogenic properties might 
avoid the need for treating valve 
recipients with anticoagulants.
There were, however, several 
major hurdles to development. First, 
an abundant supply of non-human 
valves with size and hemodynamic 
properties suitable to the human 
heart would be required. After evalu-
ation of a number of possibilities, 
the pig was identified as an attrac-
tive source: supply was abundant, 
and the valve size and hemody-
namic properties proved well-suited 
to function in the human heart. This 
left two daunting problems: antige-
nicity of the xenograft and durability. 
Not surprisingly, the foreign antigens 
of a porcine valve had the capac-
ity to incite a brisk inflammatory 
response, ultimately destroying the 
implanted valve. Moreover, because 
the implanted valve was biologically 
inactive, degradation of its collagen 
matrix with time drastically reduced 
its useful life after implantation.
Initial efforts to increase valve dura-
bility entailed treatment with mercury. 
These valves were the first xenografts 
implanted into humans, in 1965; 
unfortunately, they continued to elicit 
an inflammatory response, resulting 
in valve degeneration over short time 
periods (Binet et al., 1965). Recogniz-
ing the need for improved methods of 
valve preparation, Carpentier sought training in chemistry to advance 
these studies, ultimately receiving 
a PhD from the University of Paris. 
Through experimentation with a vari-
ety of agents, he showed that cross-
linking with glutaraldehyde offered 
virtual elimination of valve antigenic-
ity (Carpentier et al., 1969) as well as 
dramatically increased valve durabil-
ity. In addition, recognizing the key 
role of invasion of inflammatory cells 
at the surgical margin, Carpentier 
mounted the valves on a prosthetic 
stent, which reduced inflammatory 
reactions and also facilitated surgical 
implantation of the valve (Figure 3).
The first glutaraldehyde-treated 
valves were implanted into humans 
in 1968 and resulted in long-term 
survival without anticoagulation. The 
success of these xenografts was first 
reported in 1969 (Carpentier et al., 
1969), and these valves were com-
mercialized and made available for 
general use. Carpentier and his col-
leagues documented the long-term 
outcome of these patients (Carpentier 
et al., 1974). Compared with mechani-
cal valves, these bioprosthetic valves 
did not require anticoagulation, elimi-
nating the increased risk of hemor-
rhage and likely reducing the risk 
of thromboembolism. On the other 
hand, xenografts were not perfect: 
they were substantially less durable 
than mechanical valves, initially with 
an expected lifetime of about 15 
years. Moreover, for uncertain rea-
sons, xenografts in young people are 
prone to calcify, making them unsuit-
able for insertion in young patients. 
Carpentier has continued to refine 
Figure 3. The carpentier Porcine  
Bioprosthetic Valve
The image shows a glutaraldehyde-fixed por-
cine valve mounted on a prosthetic stent. Im-
age courtesy of Edwards Lifesciences.Cell 130, Septthe bioprosthetic valve to address 
these issues, developing a bovine 
pericardial bioprosthesis with greater 
durability (Perier et al., 1991) and 
developing high-temperature fixation 
procedures that have been shown to 
reduce valve calcification (Carpentier 
et al., 1998).
Despite all of these advances with 
valve replacement, Carpentier rec-
ognized the intrinsic superiority of 
the native valve to any replacement 
and observed that in many cases of 
degenerative mitral valve regurgita-
tion, the primary problem was a dilated 
mitral valve annulus, with otherwise 
normal valve leaflets. Accordingly, he 
developed a prosthetic annulus (uni-
versally known as the Carpentier ring) 
and showed that its implantation can 
restore valve function with preserva-
tion of the native valve (Carpentier 
et al., 1971). This repair procedure 
has become the treatment of choice 
for most patients with degenerative 
mitral valve regurgitation.
Starr and Carpentier revolutionized 
the treatment of valvular heart dis-
ease. Their bodies of work are each 
extraordinary for their broad embrace 
of interdisciplinary research, com-
bined with intuition, focus, and care-
ful experimentation. Their efforts 
have had enormous worldwide 
impact, with ~450,000 patients ben-
efiting from valve surgery each year. 
These interventions are life-saving 
and dramatically improve the quality 
of life of recipients. Starr and Carpen-
tier are richly deserving recipients of 
this year’s Lasker Award for Clinical 
Medical Research.
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